Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 1, 2006, Pages 98-104

  Pearlman, David S ^a   Van Adelsberg, Janet ^b   Philip, George ^b   Tilles, Stephen A ^c   Busse, William ^d   Hendeles, Leslie ^e   Loeys, Thomas ^b   Dass, S Balachandra ^b   Reiss, Theodore F ^b  

^a Respiratory Institute   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Northwest Asthma and Allergy   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; PLACEBO; SALBUTAMOL; SALMETEROL;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE INDUCED ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 33746586520     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61377-4     Document Type: Article

References (37)

1. Gotshall RW. Exercise-induced bronchoconstriction. Drugs. 2002;62:1725-1739.
2. Hallstrand TS, Moody MW, Wurfel MM, Schwartz LB, Henderson WR Jr, Aitken ML. Inflammatory basis of exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2005;172:679-686.
3. Beck KC. Control of airway function during and after exercise in asthmatics. Med Sci Sports Exerc. 1999;31:S4-S11.
4. Kikawa Y, Miyanomae T, Inoue Y, et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 1992;89:1111-1119.
5. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997;52:1030-1035.
6. Israel E. Moderating the inflammation of asthma: inhibiting the production or action of products of the 5-lipoxygenase pathway. Ann Allergy. 1994;72:279-284.
7. O'Byrne PM. Exercise-induced bronchoconstriction: elucidating the roles of leukotrienes and prostaglandins. Pharmacotherapy. 1997;17:31S-38S.
8. Anderson SD. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med. 2004;3:365-379.
9. Moraes TJ, Selvadurai H. Management of exercise-induced bronchospasm in children: the role of leukotriene antagonists. Treat Respir Med. 2004;3:9-15.
10. 2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol. 2000;106:500-506.
11. Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr. 1999;134:273-279.
12. Lehnigk B, Rabe KF, Dent G, Herst RS, Carpentier PJ, Magnussen H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J. 1998;11:617-623.
13. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931-935.
14. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J. 1999;14:12-18.
15. Reiss TF, Knorr B, Malmstrom K, Noonan G, Lu S. Clinical efficacy of montelukast in adults and children. Clin Exp Allergy Rev. 2001;1:264-273.
16. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
17. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. 1998;133:424-428.
18. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147-152.
19. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized double-blind trial. Ann Intern Med. 2000;132:97-104.
20. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med. 1994;330:1362-1367.
21. Anderson SD, Brannan JD. Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future. Paediatr Drugs. 2004;6:161-175.
22. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003;167:528-533.
23. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist. N Engl J Med. 1990;323:1736-1739.
24. Knorr B, Holland S, Schwartz J, Rogers JD, Reiss TF. Clinical pharmacology of montelukast. Clin Exp Allergy Rev. 2001;1:254-260.
25. Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, Cmiel A, Szczeklik A. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy. 2002;32:1360-1365.
26. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther. 1997;62:556-561.
27. Wilkerson LA. Exercise-induced asthma. J Am Osteopath Assoc. 1998;98:211-215.
28. Weiler JM. Exercise-induced asthma: a practical guide to definitions, diagnosis, prevalence, and treatment. Allergy Asthma Proc. 1996;17:315-325.
29. Spooner CH, Spooner GR, Rowe BH. Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. Cochrane Database Syst Rev. 2003;4:CD002307.
30. Kelly K, Spooner CH, Rowe BH. Nedocromil sodium vs. sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics. Cochrane Database Syst Rev. 2000;4:CD002731.
31. Tan RA, Spector SL. Exercise-induced asthma. Sports Med. 1998;25:1-6.
32. Mahler DA. Exercise-induced asthma. Med Sci Sports Exerc. 1993;25:554-561.
33. Belcher NG, O'Hickey S, Arm JP, Lee TH. Pathogenetic mechanisms of exercise-induced asthma and the refractory period. N Engl Reg Allergy Proc. 1988;9:199-201.
34. Godfrey S, Silverman M. Demonstration by placebo response in asthma by means of exercise testing. J Psychosom Res. 1973;17:293-297.
35. Sears MR, Lotvall J. Past, present and future-beta2-adrenoceptor agonists in asthma management. Respir Med. 2005;99:152-170.
36. Price JF. Choices of therapy for exercise-induced asthma in children. Allergy. 2001;56:12-17.
37. Villaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol. 1999;104:547-553.